Lumibird Medical, the parent company of Quantel Medical and Ellex, announced the opening of its new Indian subsidiary in Mumbai: Lumibird Medical India.
This company aims to boost sales of Quantel Medical and Ellex products in India with a shared range of ultrasound platforms, ophthalmic lasers, and equipment for the diagnosis and treatment of dry eye.
Ophthalmology-based diseases in India are increasing, according to Lumibird. Annually, close to 5 million cataract surgeries are performed in India. A study done by L V Prasad Eye Institute (LVPEI), Hyderabad, published in 2019, stated that by the year 2030, 275 million people are expected to be affected by dry eye disease.
There is a significant and growing burden of moderate visual impairment in India. Based upon increasing burden of eye diseases and moderate growth in technological advancements, the market is expected to register a CAGR of 7.3%.
“We have been operating in the Indian market for more than 25 years and are the leading provider of ophthalmic ultrasound systems”, says Jean-Marc Gendre, CEO of Lumibird Medical. “Given the growth that the Indian ophthalmology market is currently experiencing, we’ve decided to set up our own subsidiary and directly address the needs of Indian ophthalmologists for diagnosis and treatment products for retinal diseases, glaucoma, AMD, cataracts and dry eye”.
The ranges of Lumibird Medical products are available for purchase via 100 independent distributors in over 110 countries as India and for direct purchase in France, Poland, Sweden, Norway, Finland, the United States, Australia and Japan.
Lumibird Medical will take part at the AIOC Congress starting June 2, where Quantel Medical’s and Ellex's latest innovations will be exhibited. Among them, a specific focus on the CSTIM IPL System for dry eye treatment and the new biometer AXIalis from Quantel Medical.